Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Pharmacol ; 728: 31-8, 2014 Apr 05.
Artigo em Inglês | MEDLINE | ID: mdl-24486705

RESUMO

Adenosine A2A receptors are predominantly localized on striatopallidal gamma-aminobutyric acid (GABA) neurons, where they are colocalized with dopamine D2 receptors and are involved in the regulation of movement. Adenosine A2A receptor antagonists have been evaluated as a novel treatment for Parkinson's disease and have demonstrated efficacy in a broad spectrum of pharmacological and toxicological rodent and primate models. Fewer studies have been performed to evaluate the efficacy of adenosine A2A receptor antagonists in genetic models of hypodopaminergic states. SCH 412348 is a potent and selective adenosine A2A receptor antagonist that shows efficacy in rodent and primate models of movement disorders. Here we evaluated the effects of SCH 412348 in the MitoPark mouse, a genetic model that displays a progressive loss of dopamine neurons. The dopamine cell loss is associated with a profound akinetic phenotype that is sensitive to levodopa (l-dopa). SCH 412348 (0.3-10mg/kg administered orally) dose dependently increased locomotor activity in the mice. Moreover, SCH 412348 retained its efficacy in the mice as motor impairment progressed (12-22 weeks of age), demonstrating that the compound was efficacious in mild to severe Parkinson's disease-like impairment in the mice. Additionally, SCH 412348 fully restored lost functionality in a measure of hind limb bradykinesia and partially restored functionality in a rotarod test. These findings provide further evidence of the anti-Parkinsonian effects of selective adenosine A2A receptor antagonists and predict that they will retain their efficacy in both mild and severe forms of motor impairment.


Assuntos
Antagonistas do Receptor A2 de Adenosina/uso terapêutico , Antiparkinsonianos/uso terapêutico , Transtornos Parkinsonianos/tratamento farmacológico , Pirimidinas/uso terapêutico , Receptor A2A de Adenosina/metabolismo , Triazóis/uso terapêutico , Antagonistas do Receptor A2 de Adenosina/administração & dosagem , Antagonistas do Receptor A2 de Adenosina/farmacologia , Animais , Antiparkinsonianos/administração & dosagem , Antiparkinsonianos/farmacologia , Relação Dose-Resposta a Droga , Globo Pálido/metabolismo , Hipocinesia/induzido quimicamente , Masculino , Camundongos , Camundongos Endogâmicos , Atividade Motora/efeitos dos fármacos , Transtornos Parkinsonianos/metabolismo , Transtornos Parkinsonianos/fisiopatologia , Ligação Proteica , Pirimidinas/administração & dosagem , Pirimidinas/farmacologia , Teste de Desempenho do Rota-Rod , Triazóis/administração & dosagem , Triazóis/farmacologia , Ácido gama-Aminobutírico/metabolismo
2.
BMC Neurosci ; 14: 90, 2013 Aug 28.
Artigo em Inglês | MEDLINE | ID: mdl-23981345

RESUMO

BACKGROUND: Drugs targeting insomnia ideally promote sleep throughout the night, maintain normal sleep architecture, and are devoid of residual effects associated with morning sedation. These features of an ideal compound are not only dependent upon pharmacokinetics, receptor binding kinetics, potency and pharmacodynamic activity, but also upon a compound's mechanism of action. RESULTS: Dual orexin receptor antagonists (DORAs) block the arousal-promoting activity of orexin peptides and, as demonstrated in the current work, exhibit an efficacy signal window dependent upon oscillating levels of endogenous orexin neuropeptide. Sleep efficacy of structurally diverse DORAs in rat and dog was achieved at plasma exposures corresponding to orexin 2 receptor (OX2R) occupancies in the range of 65 to 80%. In rats, the time course of OX2R occupancy was dependent upon receptor binding kinetics and was tightly correlated with the timing of active wake reduction. In rhesus monkeys, direct comparison of DORA-22 with GABA-A modulators at similar sleep-inducing doses revealed that diazepam produced next-day residual sleep and both diazepam and eszopiclone induced next-day cognitive deficits. In stark contrast, DORA-22 did not produce residual effects. Furthermore, DORA-22 evoked only minimal changes in quantitative electroencephalogram (qEEG) activity during the normal resting phase in contrast to GABA-A modulators which induced substantial qEEG changes. CONCLUSION: The higher levels of receptor occupancy necessary for DORA efficacy require a plasma concentration profile sufficient to maintain sleep for the duration of the resting period. DORAs, with a half-life exceeding 8 h in humans, are expected to fulfill this requirement as exposures drop to sub-threshold receptor occupancy levels prior to the wake period, potentially avoiding next-day residual effects at therapeutic doses.


Assuntos
Azepinas/farmacocinética , Antagonistas dos Receptores de Orexina , Sono/efeitos dos fármacos , Triazóis/farmacocinética , Animais , Cães , Eletroencefalografia , Feminino , Humanos , Imunoensaio , Peptídeos e Proteínas de Sinalização Intracelular/líquido cefalorraquidiano , Macaca mulatta , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Neuropeptídeos/líquido cefalorraquidiano , Orexinas , Ratos , Ratos Sprague-Dawley , Ratos Transgênicos , Sono/fisiologia
3.
Opt Express ; 20(2): 1691-9, 2012 Jan 16.
Artigo em Inglês | MEDLINE | ID: mdl-22274511

RESUMO

We propose and demonstrate a novel scheme for obtaining quasi-uniform rate polarization scrambling at up to 752 krad/s in fiber optic systems by using cascaded multiple fiber squeezers with each one placed in a certain orientation. Additionally, this polarization scrambler is compatible with both single-polarization and polarization-multiplexing systems. We also show that scrambled SOP with this scheme uniformly covers the whole Poincare Sphere and that the scrambling rates are mostly concentrated towards the high end of the rate distribution histogram. Such a scrambling scheme is advantageous for the deterministic characterization of performances for modern fiber optic transceivers, especially those deploying coherent detection techniques, against rapid polarization variations.


Assuntos
Tecnologia de Fibra Óptica/instrumentação , Tecnologia de Fibra Óptica/métodos , Fibras Ópticas , Telecomunicações/instrumentação , Simulação por Computador , Desenho de Equipamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...